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j ourna l homepage: www.e lsev ie r .com/ locate /atgUnsung heroes: Genomic successes in the developing worldRecounting progress in genomics typically involves detailing a series
of milestones from the inception of the Human Genome Project to the
present. Eric Lander did just that beautifully in his plenary talk opening
the recent International Congress onHumanGenetics 2016 in Kyoto. He
traced the path from genetics to disease biology as it progressed from
identifying disease genes to sequencing genomes, to mapping disease
genes, to cataloging common and rare genetic variations to interpreting
their clinical signiﬁcance, to understanding how the genome folds into
3D maps, all of which bespeaks remarkable achievements, and innova-
tion, in science and patient care. Not surprisingly, such regaling of suc-
cess rarely if ever includes achievements by less resourced countries,
because resource limitations for the most part bar contributions of the
same magnitude. The challenges faced by researchers in these parts of
the world are more readily known than the successes, however large
or small. It is for this reason that we bring to your attention remarkable
achievements occurring in such areas of the world.
In this special issue of the Journal several groups from developing
countries from across the globe report their work and perspectives. In
‘Pharmacogenomics for infectious diseases in sub-Saharan Africa suc-
cesses & opportunities’, Chaudhry and colleagues from South Africa,
while addressing both the potential of pharmacogenomics as well as
its failure to live up to initial expectations, highlight the fact that
international consortia working on pharmacogenomic implementation
guidelines have failed to come up with guidelines for the major
infectious disorders affecting the developing world such as HIV/AIDS,
TB, and malaria.
In the globalized world that we live in, international collaboration is
the key to success. Limited research infrastructures as well as, poorly
developed research and ethics governance mechanisms pose many
challenges for both researchers and ethics committees. Roach and
colleagues, in their paper ‘Addressing ethical challenges in the genetics
sub study of the national eye survey of Trinidad and Tobago’ highlight
some of these challenges while demonstrating their novel approaches
to developing a culturally appropriate, multifaceted strategy to address
these challenges.
In today's world the buzzword is genomic medicine. Genomic med-
icine is dependent on successful implementation of genome sequencing
and clinical bioinformatics. At the recent International Congress of
Human Genetics 2016 several plenary speakers declared, “Doctors are
good, but exomes are better”. Genomic data driven medicine can only
be a reality in settings where infrastructure and manpower for genome
sequencing and clinical bioinformatics is in place. Helmy and colleagues
from Egypt and the UAE provide their perspectives on the challenges
faced by the developing world in making genomic medicine a reality
due to limited infrastructure for genome sequencing and bioinformat-
ics, and suggest solutions to overcome them, in their article ‘Limited
resources of genomic tools in developing countries: challenges
and solutions’.http://dx.doi.org/10.1016/j.atg.2016.05.002
2212-0661/© 2016 The Authors. Published by Elsevier B.V. This is an open access article underDespite signiﬁcant resource limitations, there are oases of excellence
in genomic research in the developing world. These three papers
illustrate the breadth of research and depth of success; speciﬁcally in fo-
rensic genomics, clinical informatics and agrigenomics/bioinformatics.
Mohamed and Salama present evidence of the affection of tau normal
pattern and pathological aggregates of tau in case of brain hypoxia
and suggest therefore that tau protein may be a biomarker for asphyxia
in ‘Tau protein as a biomarker for asphyxia: A possible forensic tool.’
Mulder and colleagues from both the Sickle Cell Disease (SCD) commu-
nity and H3ABioNet report on their recent SCD Ontologyworkshop that
produced the ﬁrst comprehensive SCD ontology, in ‘Proceedings of a
sickle cell disease ontology workshop- towards the ﬁrst comprehensive
ontology for sickle cell disease’. The ontology permits improved data
sharing, meta-analyses and further development and curation of
databases and clinical informatics. As such it can serve as a model for
other disease communities. Tospovirus is severe plant pathogen
that damages food crops worldwide. In ‘SeeHaBITaT: a server on bioin-
formatics applications for tospoviruses and other species’, Habeeb,
presents a novel server that enables both control measures and the
capacity for other computational research where none had existed.
The challenge to take research from bench to bedside is always
formidable and all the more so in resourced constrained countries. In
their paper ‘Implementation of genomic medicine in Sri Lanka: initial
experience and challenges’, Sirisena and colleagues describe how they
used clinical exome sequencing and gene panel testing to diagnose
three complex cases leading to improved patient care. Such experiences
are for most part isolated and therefore there is a need for more
widespread equitable implementation of genomic medicine. The ﬁnal
paper by Isaacson Barash ‘Translating translational medicine into global
equity: what is needed?’ provides insights about what is needed to
achieve widespread equitable implementation of genomic medicine,
based on a survey of unmet needs at last fall's Asia Paciﬁc Society of
Human Genetics meeting 2015 in Hanoi.
To be sure, the successes reported here are signiﬁcant. And yet, it is
still necessary to ask why Genomic Medicine is lagging behind in the
less resourced parts of the world. Most developing countries around
the world today have large expatriate populations living in the West
or afﬂuent countries in the Middle East, working as migrant workers.
Often such trained individuals return to their native countries to bring
new knowledge and skills to ﬁll the void. Further, increasingly, there
is pressure for services available in the West to be made available in
developing countries. And yet despite the rapid adoption of IT and
increases in global collaborations and data sharing, genomic medicine
is not keeping pace outside the West.
The national health agenda of most developing countries is shaped
by technical assistance given by the World Health Organization
(WHO). Sadly, the WHO has been slow to embrace Genomic Medicine
and the Human Genetics Program at the WHO has been poorly staffed
and poorly funded. The global agenda of the WHO is shaped bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2resolutions of theWorld Health Assembly (WHA). Action based on such
resolutions received funding, and are implemented through the
regional organizations of the WHO. In case of Genomic Medicine,
there is no such WHA resolution. The only resolution that comes close
to genetics and genomics is the resolution calling on Member States to
help redress the limited focus to date on preventing and managing
birth defects, especially in low- and middle-income countries. This
resolution, made at the 63rd WHA in May 2010, called on Member
States to prevent birth defects wherever possible, to implement
screening programs, and to provide ongoing support and care to
children with birth defects and their families (http://apps.who.int/gb/
ebwha/pdf_ﬁles/WHA63/A63_R17en.pdf) On the ground in most
countries this translated into efforts aimed at strengthening birth
defects surveillance (World Health Organization Regional Ofﬁce for
Southeast Asia, 2013). We urge the various international groups that
are working on Genomics and Health to now focus their attention on
lobbying the WHO for a global plan of action for implementation of
genomic medicine with special focus on low- and middle-income
countries. This special issue serves to demonstrate that the need, desire
and capacity to implement genomic medicine in low- and middle-
income countries are there. With the help of the WHO, equitable
implementation of genomic medicine is more likely.
In conclusion, this special issue captures several translational
genetics and genomics success stories from the developing world. The
ultimate beneﬁciaries of this work have to be the people at large. Thatwould happen only in the context of a healthcare workforce that is
trained to use genetic and genomic information in their professional
practice. That has its own challenges which were highlighted in a
previous issue of this journal by de Abrew et al. (2014) Imparting the
necessary knowledge, skills and experience on the healthcare
workforce to implement genomic medicine is one of the biggest
challenges facing the world today and we plan to deal with this
fully in another special issue of the journal in the future.
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